Invivyd, Inc. (IVVD) Form 8-K — Aug 13, 2026
Invivyd (Nasdaq: IVVD) reported Q2 2026 PEMGARDA net product revenue of $14.3 million, up 21% from $11.8 million in Q2 2025, driven by increased patient demand. The company skipped a Q2 earnings call and plans an investor call after the pivotal DECLARATION study wraps, with top-line data expected later in Q3 2026. Net loss widened to $44.4 million, or $0.14 per share, from $14.7 million, or $0.12 per share, a year ago, as R&D expense nearly tripled to $29.4 million and SG&A rose to $29.5 million on DECLARATION and LIBERTY trial costs and commercial build-out. Weighted-average shares of 320.4 million were roughly 2.7x the year-ago 120.0 million, reflecting substantial prior dilution.
Key figures
- Revenue
- 14285000
- Revenue Yoy
- 21%
- Total Assets
- 218883000
- Cash Position
- 160080000
- Shares Outstanding
- 294755090
- Cash runway
- through DECLARATION pivotal data readout and to support potential commercial launch readiness for VYD2311
- Revenue q2 2025
- 11786000
- Cash dec 31 2025
- 226689000
- Net loss q2 2025
- 14660000
- Total liabilities
- 37803000
- Rnd expense q2 2025
- 9573000
- Rnd expense q2 2026
- 29367000
- Sga expense q2 2025
- 16588000
- Sga expense q2 2026
- 29465000
- Top line data timing
- DECLARATION and LIBERTY top-line data anticipated later in Q3 2026
- Six month net loss 2026
- 85793000
- Liberty trial enrollment
- approximately 210 participants
- Total stockholders equity
- 181080000
- Rsv market projection 2030
- $3-$4 billion annual revenue globally
- Weighted avg shares q2 2025
- 120016132
- Weighted avg shares q2 2026
- 320435078
- Declaration trial enrollment
- approximately 2,400 participants
- Eua termination effective date
- June 29, 2027
- Six month product revenue 2026
- 28029000
Price after filing
Close on the filing date to close N calendar days later (from $0.69). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.